• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

幽门螺杆菌根除后胃增生性息肉的消失。一项随机临床试验。

Disappearance of hyperplastic polyps in the stomach after eradication of Helicobacter pylori. A randomized, clinical trial.

作者信息

Ohkusa T, Takashimizu I, Fujiki K, Suzuki S, Shimoi K, Horiuchi T, Sakurazawa T, Ariake K, Ishii K, Kumagai J, Tanizawa T

机构信息

Tokyo Medical and Dental University School of Medicine, Japan.

出版信息

Ann Intern Med. 1998 Nov 1;129(9):712-5. doi: 10.7326/0003-4819-129-9-199811010-00006.

DOI:10.7326/0003-4819-129-9-199811010-00006
PMID:9841603
Abstract

BACKGROUND

Helicobacter pylori infection is common in patients with hyperplastic gastric polyps.

OBJECTIVE

To study the effect of eradication of H. pylori on the clinical course of patients with hyperplastic gastric polyps.

DESIGN

Single-blind, randomized, controlled trial.

SETTING

University-based gastroenterology outpatient clinic.

PATIENTS

35 patients with H. pylori infection and hyperplastic gastric polyps at least 3 mm in diameter.

INTERVENTION

Patients were randomly assigned to a treatment group (n = 17), which received a proton-pump inhibitor (omeprazole or lansoprazole), amoxicillin, and either clarithromycin or ecabet sodium, or to a control group (n = 18), which received no treatment.

MEASUREMENTS

Patients underwent endoscopy before enrollment and 12 to 15 months after the end of treatment. Serum gastrin levels and titers of IgG to H. pylori were measured.

RESULTS

In the treatment group, the polyps had disappeared by 3 to 15 months (average, 7.1 +/- 1.2 months) after the end of treatment in 12 of all 17 patients (71%) and in 12 of the 15 patients (80%) in whom H. pylori was eradicated. However, 12 to 15 months after the start of the study, no change in polyps or H. pylori status was seen in any controls (P < 0.001). Histologic findings of inflammation and activity, serum gastrin levels, and titers of IgG to H. pylori showed significant regression in the treatment group compared with the control group (P < 0.01).

CONCLUSIONS

Most hyperplastic polyps disappeared after eradication of H. pylori. Thus, eradication should be attempted before endoscopic removal is done in patients with hyperplastic gastric polyps and H. pylori infection.

摘要

背景

幽门螺杆菌感染在增生性胃息肉患者中很常见。

目的

研究根除幽门螺杆菌对增生性胃息肉患者临床病程的影响。

设计

单盲、随机、对照试验。

地点

大学附属医院胃肠病门诊。

患者

35例幽门螺杆菌感染且有直径至少3毫米增生性胃息肉的患者。

干预措施

患者被随机分为治疗组(n = 17),接受质子泵抑制剂(奥美拉唑或兰索拉唑)、阿莫西林以及克拉霉素或依卡倍特钠治疗;或对照组(n = 18),不接受治疗。

测量指标

患者在入组前以及治疗结束后12至15个月接受内镜检查。检测血清胃泌素水平以及幽门螺杆菌IgG抗体滴度。

结果

治疗组中,17例患者中的12例(71%)在治疗结束后3至15个月(平均7.1±1.2个月)息肉消失,在根除幽门螺杆菌的15例患者中的12例(80%)息肉消失。然而,在研究开始12至15个月后,所有对照组患者的息肉及幽门螺杆菌状态均无变化(P < 0.001)。与对照组相比,治疗组的炎症和活动度的组织学表现、血清胃泌素水平以及幽门螺杆菌IgG抗体滴度均显著改善(P < 0.01)。

结论

根除幽门螺杆菌后,大多数增生性息肉消失。因此,对于增生性胃息肉合并幽门螺杆菌感染的患者,在进行内镜切除之前应尝试根除幽门螺杆菌。

相似文献

1
Disappearance of hyperplastic polyps in the stomach after eradication of Helicobacter pylori. A randomized, clinical trial.幽门螺杆菌根除后胃增生性息肉的消失。一项随机临床试验。
Ann Intern Med. 1998 Nov 1;129(9):712-5. doi: 10.7326/0003-4819-129-9-199811010-00006.
2
Effect of drug treatment on hyperplastic gastric polyps infected with Helicobacter pylori: a randomized, controlled trial.药物治疗对幽门螺杆菌感染的增生性胃息肉的影响:一项随机对照试验。
World J Gastroenterol. 2006 Mar 21;12(11):1770-3. doi: 10.3748/wjg.v12.i11.1770.
3
Endoscopic, histological and serologic findings of gastric hyperplastic polyps after eradication of Helicobacter pylori: comparison between responder and non-responder cases.幽门螺杆菌根除后胃增生性息肉的内镜、组织学和血清学表现:应答者与无应答者病例的比较
Digestion. 2003;68(2-3):57-62. doi: 10.1159/000074516. Epub 2003 Oct 24.
4
Does the depth of gastric ulceration influence a modified dual therapy with amoxicillin and lansoprazole for Helicobacter pylori-associated gastric ulcer?胃溃疡的深度会影响阿莫西林和兰索拉唑联合的改良疗法对幽门螺杆菌相关性胃溃疡的治疗效果吗?
Can J Gastroenterol. 2000 Oct;14(9):761-6. doi: 10.1155/2000/340942.
5
Efficacy of ecabet sodium for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen.
Aliment Pharmacol Ther. 2001 Aug;15(8):1187-91. doi: 10.1046/j.1365-2036.2001.01022.x.
6
Ecabet sodium eradicates Helicobacter pylori infection in gastric ulcer patients.
J Gastroenterol. 1996 Nov;31 Suppl 9:59-62.
7
Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.CYP2C19基因分型差异对质子泵抑制剂、阿莫西林和克拉霉素三联疗法治疗幽门螺杆菌感染治愈率的影响。
Clin Pharmacol Ther. 2001 Mar;69(3):158-68. doi: 10.1067/mcp.2001.113959.
8
High-dose ecabet sodium improves the eradication rate of helicobacter pylori in dual therapy with lansoprazole and amoxicillin.
Aliment Pharmacol Ther. 2000 Nov;14(11):1523-7. doi: 10.1046/j.1365-2036.2000.00852.x.
9
Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol.通过血浆兰索拉唑水平变化和部分皮质醇清除为6β-羟基皮质醇来评估克拉霉素在幽门螺杆菌根除治疗期间对CYP3A活性的剂量依赖性抑制。
Clin Pharmacol Ther. 2002 Jul;72(1):33-43. doi: 10.1067/mcp.2002.125559.
10
Combination therapies with a proton pump inhibitor for Helicobacter pylori-infected gastric ulcer patients.质子泵抑制剂联合治疗幽门螺杆菌感染的胃溃疡患者。
J Clin Gastroenterol. 1995;20 Suppl 2:S132-5. doi: 10.1097/00004836-199506002-00036.

引用本文的文献

1
Rapid Development of a Hemorrhagic Hyperplastic Polyp in a Patient with Evolving Autoimmune Gastritis after Helicobacter pylori Eradication.幽门螺杆菌根除后自身免疫性胃炎进展期患者出血性增生性息肉的快速发展
Intern Med. 2025 Aug 15;64(16):2446-2451. doi: 10.2169/internalmedicine.4701-24. Epub 2025 Feb 8.
2
Intragastric bacterial infection and endoscopic findings in -negative patients.幽门螺杆菌阴性患者的胃内细菌感染及内镜检查结果
J Clin Biochem Nutr. 2024 Jul;75(1):65-70. doi: 10.3164/jcbn.24-56. Epub 2024 Apr 10.
3
Endoscopic findings and outcomes of gastric mucosal changes relating to potassium-competitive acid blocker and proton pump inhibitor therapy.
与钾离子竞争性酸阻滞剂和质子泵抑制剂治疗相关的胃黏膜变化的内镜检查结果及转归
DEN Open. 2024 Jun 24;5(1):e400. doi: 10.1002/deo2.400. eCollection 2025 Apr.
4
Epidemiology of Gastric Cancer: Global Trends, Risk Factors and Premalignant Conditions.胃癌流行病学:全球趋势、危险因素及癌前病变
J Community Hosp Intern Med Perspect. 2023 Nov 4;13(6):100-106. doi: 10.55729/2000-9666.1252. eCollection 2023.
5
Severe Anemia from Multiple Gastric Hyperplastic Polyps in a Hemodialysis Patient after Long-term Use of a Proton-pump Inhibitor.一名长期使用质子泵抑制剂的血液透析患者因多发性胃增生性息肉导致严重贫血
Intern Med. 2024;63(5):649-657. doi: 10.2169/internalmedicine.2091-23.
6
Helicobacter pylori eradication reduces risk for recurrence of gastric hyperplastic polyp after endoscopic resection.根除幽门螺杆菌可降低内镜切除术后胃增生性息肉复发的风险。
Korean J Intern Med. 2023 Mar;38(2):141-143. doi: 10.3904/kjim.2023.039. Epub 2023 Feb 27.
7
Helicobacter pylori eradication reduces risk for recurrence of gastric hyperplastic polyp after endoscopic resection.幽门螺杆菌根除可降低内镜切除胃增生性息肉后复发的风险。
Korean J Intern Med. 2023 Mar;38(2):167-175. doi: 10.3904/kjim.2022.111. Epub 2022 Nov 28.
8
Helicobacter pylori Modulated Host Immunity in Gastric Cancer Patients With S-1 Adjuvant Chemotherapy.幽门螺杆菌调节 S-1 辅助化疗胃癌患者的宿主免疫。
J Natl Cancer Inst. 2022 Aug 8;114(8):1149-1158. doi: 10.1093/jnci/djac085.
9
Gastric epithelial histology and precancerous conditions.胃上皮组织学与癌前病变
World J Gastrointest Oncol. 2022 Feb 15;14(2):396-412. doi: 10.4251/wjgo.v14.i2.396.
10
Case Report- A rare case of giant hyperplastic polyp.
Radiol Case Rep. 2021 Dec 1;17(2):355-359. doi: 10.1016/j.radcr.2021.10.061. eCollection 2022 Feb.